Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

• Status: Terminated
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we we prospectively want to treat these patients with avastin (and doxorubicin). However, local control is of major concern. Therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Skane
• Treatments: Bevacizumab; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• cytologically or histologically verified anaplastic thyroid cancer

• completed standard therapy

• operated with R0 or R1 surgery

• Performance Status 0-2 (if pulmonary mets PS 0-1)

• normal wound healing

• neutrophils > 1,5 million/ml

• platelets > 100 million/ml

• bilirubin < 2 ULN

• creatinin < 150mikromol/L

Exclusion Criteria:

• PS 3-4 (if pulmonary mets 2-4)

• R2 resection of primary tumor